NYSEARCA:GERM Amplify Treatments, Testing and Advancements ETF (GERM) Price, Holdings, & News $19.16 0.00 (0.00%) As of 08/28/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsBuy This Stock About Amplify Treatments, Testing and Advancements ETF (NYSEARCA:GERM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get GERM alerts:Sign Up Key Stats Today's Range$19.16▼$19.1650-Day Range$19.16▼$19.1652-Week Range$15.67▼$20.20VolumeN/AAverage Volume1,891 shsMarket Capitalization$9.58 millionAssets Under Management$9.67 millionDividend Yield1.20%Net Expense Ratio0.68%Aggregate RatingN/A ETF Overview The ETFMG Treatments, Testing and Advancements ETF (GERM) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases. GERM was launched on Jun 17, 2020 and is managed by ETF Managers Group. Read More Amplify Treatments, Testing and Advancements ETF ExpensesTypeGERMTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.68%0.57%0.56%0.51%0.53%Other Expenses0.00%0.57%0.56%0.59%0.56%Total Expense0.68%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.76%-0.66%-0.71%-0.63%Net Expense0.68%0.60%0.63%0.58%0.60% Receive GERM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amplify Treatments, Testing and Advancements ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GERM ETF News HeadlinesAmplia Therapeutics Advances Cancer Drug TrialOctober 30, 2024 | markets.businessinsider.comMpox Variant Sparks Global Concern As Europe, China Ramp Up ScreeningAugust 19, 2024 | benzinga.comAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.August 29 at 2:00 AM | Paradigm Press (Ad)Amplify ETFs to Liquidate Three ETFsAugust 15, 2024 | finance.yahoo.comTHNR Amplify Weight Loss Drug & Treatment ETFAugust 1, 2024 | seekingalpha.comETFMG Treatments Testing and Advancements ETFFebruary 11, 2024 | thestreet.comSee More Headlines GERM ETF - Frequently Asked Questions How have GERM shares performed this year? Amplify Treatments, Testing and Advancements ETF's stock was trading at $19.1577 on January 1st, 2025. Since then, GERM shares have increased by 0.0% and is now trading at $19.1577. How do I buy shares of Amplify Treatments, Testing and Advancements ETF? Shares of GERM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amplify Treatments, Testing and Advancements ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amplify Treatments, Testing and Advancements ETF investors own include Moderna (MRNA), PayPal (PYPL), Global X Robotics & Artificial Intelligence ETF (BOTZ), Walt Disney (DIS), NVIDIA (NVDA), Tesla (TSLA) and AbbVie (ABBV). Fund Details IssuerAmplify Fund NameAmplify Treatments, Testing and Advancements ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:GERM Inception Date6/17/2020 Fund ManagerCharles Ragauss, Qiao Duan WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkPrime Treatments, Testing and Advancements Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings2 Fund Statistics Assets Under Management$9.67 million Average Daily Volume$0.00 Discount/Premium-0.18% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorAmplify Investments LLC CustodianU.S. Bank, N.A. DistributorForeside Fund Services, LLC Transfer AgentU.S. Bancorp Fund Services, LLC TrusteeN/A Lead Market MakerVirtu Financial Options OptionableN/A Short Interest100 shs Miscellaneous Outstanding Shares500,000Beta0.84 Creation Unit50,000 Creation Fee$300.00 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report Top 4 GERM HoldingsInvesco Government & Agency Portfolio 12/31/2031Holding Weight: 99.70%Cash & OtherHolding Weight: 0.30%AstraZeneca PLCHolding Weight: 0.00%Gurnet Point Capital LLCHolding Weight: 0.00%Full Holdings Details This page (NYSEARCA:GERM) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Treatments, Testing and Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Treatments, Testing and Advancements ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access